indazoles has been researched along with Hormone-Dependent Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bundred, N; Butler, H; Derynck, M; Earl, G; Gazinska, P; Gendreau, S; Hadad, S; Hu, J; Korbie, D; Lackner, MR; Lim, L; Macaskill, J; Mainwaring, P; Parker, P; Pinder, SE; Price, R; Purushotham, A; Sarker, SJ; Schmid, P; Shia, A; Thompson, A; Trau, M; Wheatley, D; Wilson, TR; Woodman, N; Zammit, C | 1 |
| Kraut, E; Moore, T; Philip Kuebler, J; Pritchard, J | 1 |
2 trial(s) available for indazoles and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Combined Modality Therapy; Drug Synergism; Female; Humans; Indazoles; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Phosphoinositide-3 Kinase Inhibitors; Postmenopause; Preoperative Care; Protein Kinase Inhibitors; Receptor, ErbB-2; Receptors, Estrogen; Sulfonamides; Triazoles | 2016 |
Phase II study of CI-958 in patients with hormone refractory prostate carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Drug Resistance, Neoplasm; Drugs, Investigational; Humans; Indazoles; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms | 2004 |